- Home
- VYX vs MYGN Comparison
VYX vs MYGN Comparison
Compare VYX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYX
- MYGN
- Stock Information
- Founded
- VYX 1881
- MYGN 1991
- Country
- VYX United States
- MYGN United States
- Employees
- VYX N/A
- MYGN N/A
- Industry
- VYX
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- VYX
- MYGN Health Care
- Exchange
- VYX Nasdaq
- MYGN Nasdaq
- Market Cap
- VYX 2.0B
- MYGN 2.0B
- IPO Year
- VYX N/A
- MYGN 1995
- Fundamental
- Price
- VYX $13.96
- MYGN $15.25
- Analyst Decision
- VYX Strong Buy
- MYGN Buy
- Analyst Count
- VYX 7
- MYGN 12
- Target Price
- VYX $16.33
- MYGN $27.64
- AVG Volume (30 Days)
- VYX 1.3M
- MYGN 990.7K
- Earning Date
- VYX 11-07-2024
- MYGN 11-07-2024
- Dividend Yield
- VYX N/A
- MYGN N/A
- EPS Growth
- VYX N/A
- MYGN N/A
- EPS
- VYX 4.40
- MYGN N/A
- Revenue
- VYX $3,592,000,000.00
- MYGN $823,600,000.00
- Revenue This Year
- VYX N/A
- MYGN $13.85
- Revenue Next Year
- VYX N/A
- MYGN $7.73
- P/E Ratio
- VYX $3.21
- MYGN N/A
- Revenue Growth
- VYX 956.47
- MYGN 12.15
- 52 Week Low
- VYX $10.87
- MYGN $15.18
- 52 Week High
- VYX $17.39
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- VYX 55.79
- MYGN 16.18
- Support Level
- VYX $13.96
- MYGN $16.86
- Resistance Level
- VYX $14.70
- MYGN $19.60
- Average True Range (ATR)
- VYX 0.48
- MYGN 1.17
- MACD
- VYX 0.10
- MYGN -0.25
- Stochastic Oscillator
- VYX 65.19
- MYGN 0.90
About VYX NCR Voyix Corporation
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.